Juniper Pharma Services expands laboratory facilities

Juniper Pharma Services expands laboratory facilities to meet with growing demand

Nottingham, UK – Juniper Pharma Services (JPS), a Contract Development and Manufacturing Organisation (CDMO) specialising in the development of challenging small molecules, has announced a significant expansion to its UK-based drug development and clinical trial manufacturing facilities.

The extension provides four additional process development laboratories at its Nottingham site, improving the output and efficiency of its development and clinical manufacturing operations.

Set to be fully operational by summer 2018, the new laboratory space will allow Juniper Pharma Services to work with an ever-growing client base to transform poorly soluble and difficult to formulate molecules into successful products. The expansion will ensure that processing and formulation work is scalable, enabling the efficient manufacture of stability and clinical batches.

The expansion demonstrates Juniper Pharma Services’ growth in the drug development arena and its increasing commitment to solving tough formulation challenges.

 The new facilities, combined with Juniper Pharma Services long-standing expertise in drug formulation development, is desirable to many pharmaceutical clients and enhances the company’s reputation as a leading CDMO in the UK and globally.

Nikin Patel, President at Juniper Pharma Services, commented: “We are always exploring opportunities to extend our service offerings to meet the evolving requirements of our market and clients. This facility expansion, which has significantly increased Juniper Pharma Services’ capacity, is the latest effort in this endeavour.”

See more Pharmaceutical Cleanroom Industry News

Source: Juniper Pharma Services

Keywords: Laboratory expansion, pharmaceutical cleanroom expansion, pharma cleanroom, laboratory facility, laboratory facility expansion

About Juniper Pharma Services

Juniper Pharma Services

Juniper Pharmaceuticals’ (Nasdaq: JNP) core businesses include its CRINONE® (progesterone gel) franchise and Juniper Pharma Services, which provides high-end, fee-for-service pharmaceutical development and clinical trials manufacturing to clients.

The Company has a successful history in developing pharmaceutical products, including Crinone® 8% (progesterone gel), which is commercially available in the United States and over 90 countries around the world.

We provide high end services including pharmaceutical developmentclinical trial supply manufacturing, and analytical capabilities to clients, while also providing  valuable intellectual property-related consultative services to our pharmaceutical industry customers.

Juniper is positioned for success with a highly experienced leadership team in combination with a solid balance sheet and strong cash flows to build our core business and create long term value.

Crinone® is a registered trademark of Merck KGaA, Darmstadt, Germany, outside the U.S. and of Allergan, Inc. in the U.S.